Regulatory Issues: PMDA – Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma

In June 2021, the Ministry of Health, Labor and Welfare approved Delytact Injection as a regenerative medical product for oncolytic virus therapy. The active substance of Delytact Injection is teserpaturev, a genetically engineered herpes simplex virus type 1 (strain F) in which the α47 gene and bot...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Yoshiaki, Sakurai, Akira, Noda, Shinichi, Fujiwara, Yasuhiro, Okura, Narumi, Takagi, Toshinori, Asano, Junichi, Honda, Futaba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Regulatory Issues
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400161/
https://www.ncbi.nlm.nih.gov/pubmed/36917020
http://dx.doi.org/10.1093/oncolo/oyad041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400161/
https://www.ncbi.nlm.nih.gov/pubmed/36917020
http://dx.doi.org/10.1093/oncolo/oyad041

Ejemplares similares